Inventiva (NASDAQ:IVA) Trading Up 10.8% – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price was up 10.8% on Monday . The stock traded as high as $5.83 and last traded at $5.9480. Approximately 58,752 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 422,250 shares. The stock had previously closed at $5.37.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IVA. HC Wainwright set a $24.00 target price on Inventiva and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Barclays began coverage on shares of Inventiva in a research note on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price objective on the stock. Truist Financial assumed coverage on shares of Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Inventiva presently has an average rating of “Buy” and a consensus price target of $16.56.

Inventiva Stock Down 0.9%

The business has a 50 day simple moving average of $5.68 and a 200-day simple moving average of $5.35.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The firm had revenue of $0.01 million during the quarter. Equities research analysts predict that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IVA. Creative Planning bought a new stake in shares of Inventiva during the second quarter worth $32,000. Virtu Financial LLC bought a new stake in Inventiva in the 4th quarter valued at $60,000. XTX Topco Ltd acquired a new position in Inventiva in the 4th quarter worth $84,000. Cerity Partners LLC acquired a new position in Inventiva in the 4th quarter worth $93,000. Finally, NewEdge Advisors LLC bought a new position in Inventiva during the 3rd quarter worth about $116,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.